ADC Treatment and Trials in China: Targets and Risks

Evaluate an antibody-drug conjugate by its target, antibody, linker and payload, then verify China approval, trial cohort, toxicities and monitoring.

Key takeaways

An antibody-drug conjugate (ADC) is built from three parts: a targeting antibody, a chemical linker and a potent payload. Swap any one of them and the efficacy, resistance pattern and toxicity profile can all shift.
Whether this treatment fits you can hinge on the exact tumour type, stage, treatment history, the target assay and specimen, the scoring system and its threshold. A report that only says “HER2 positive” or “TROP-2 present” may not be enough.
Approved treatment, off-label use and a clinical trial are three separate routes with different rules. Check the current Chinese indication for the exact generic product, regimen and line of therapy on the table.
Monitoring has to follow the specific product. A generic ADC checklist will not do, because lung, eye, nerve, skin, blood-count, liver, cardiac and glucose risks differ widely across agents and combinations.

Full guide

You will sometimes hear an ADC called “chemotherapy with a homing device.” The phrase only gets you partway there. An ADC is a single engineered product: an antibody chemically joined to a drug, usually a highly potent cytotoxic payload [1]. How it behaves comes down to the whole construct — what the antibody binds, how stable the linker stays in circulation, where the payload is released, how many drug molecules ride on each antibody, and what that payload does once it is free.

So the broad question “Are ADCs good?” can be skipped. The one worth asking is: “Why does this exact ADC, at this dose and in this regimen, fit my current tumour and treatment history?”

Read the drug name as three components

Component	What it controls	Questions worth asking
Antibody	Target binding, distribution and sometimes immune activity	What antigen? How much expression is required? Is the assay validated for this use?
Linker	Stability and the timing/location of payload release	Cleavable or non-cleavable? Could payload be released outside the target cell?
Payload	How cells are killed and which organs may be vulnerable	Topoisomerase inhibitor, microtubule inhibitor or another class? What prior payload exposure matters?
Drug-to-antibody ratio	Average number of payload molecules attached	How was the clinical dose selected, and which analytes were measured?

FDA’s ADC clinical-pharmacology guidance treats the intact conjugate, total antibody and free or unconjugated payload as related but distinct analytes, and it flags organ impairment, drug interactions, immunogenicity, dose/exposure-response and QT assessment as questions each product has to answer [2]. That is why safety cannot be read off the antibody target alone.

How an ADC can work

The usual sequence looks like this:

the antibody docks onto an antigen on a tumour cell;
the cell internalises the ADC-antigen complex;
intracellular trafficking carries it to a compartment where the linker or antibody is processed;
the payload is released;
the payload disrupts DNA, topoisomerase activity, microtubules or another essential process.

Released payload can also drift into nearby cells. This “bystander effect” helps when antigen expression is patchy, though it widens exposure at the same time. NCI’s discussion of trastuzumab deruxtecan describes both the target-directed internalisation and the killing of neighbouring cells with low or absent HER2 expression [3]. That behaviour belongs to that particular construct; do not assume every ADC does it.

Target testing needs exact language

A usable pathology report names the specimen, the collection date, the tumour site, the method, the antibody clone or platform where relevant, the scoring system, the result and the threshold. Before anything else, ask whether the study or label accepts archival tissue, requires a new biopsy or mandates central review.

The rules change from product to product. One may require high protein expression by immunohistochemistry, another a defined “low” category, a gene alteration or a validated companion diagnostic. Some approved indications skip routine target selection altogether even though the ADC has a named antigen. Old results can mislead too — treatment, or a different metastatic site, can change the picture.

Resist squeezing results into a positive/negative stamp. “HER2-positive,” “HER2-low” and “HER2-mutant” describe different biological and regulatory categories. The current product label or trial protocol decides which result counts.

Approved product or trial product?

For treatment in China, get all of the following on record:

Chinese generic and trade name;
marketing authorisation holder and NMPA approval number;
target, antibody, linker and payload if disclosed;
exact approved tumour type, disease setting and treatment line;
single-agent or combination regimen;
dose, schedule and required dose modifications;
current Chinese prescribing information.

A US approval, or an approval anywhere else, does not turn into a Chinese approval on its own. One approval for a molecule also covers only the tumour, biomarker level, treatment line and combination it was granted for. If the proposed use sits outside the current Chinese label, the centre has to tell you whether it counts as off-label clinical care or research, and explain the evidence, the alternatives, the consent process and who pays.

For a trial, confirm the registration number, sponsor, sites, status and study information on China’s Drug Trial Registration and Information Publication Platform [4]. Then ask for the exact cohort — the same protocol can hold several tumour types, biomarker thresholds, doses or combinations.

Trial questions that expose the real uncertainty

Early ADC studies often move both dose and schedule as they go. The highest dose is not automatically the best one; modern oncology development tries to balance activity with tolerability instead of absorbing avoidable toxicity [5]. Ask:

Which dose level or expansion cohort is open?
Is dosing based on actual body weight, adjusted weight, a cap or another rule?
What dose-limiting-toxicity window is used, and what later cumulative toxicities are tracked?
What evidence supports the target threshold and companion assay?
Is the control group standard treatment, physician’s choice, placebo plus background therapy, or another ADC?
If combined with immunotherapy or chemotherapy, which risks overlap and which component may be held first?
Are mandatory biopsies, pharmacokinetic sampling or anti-drug-antibody tests required?
What event ends treatment: progression, clinical deterioration, toxicity, maximum cycles or another rule?

Never compare response rates across trials without first checking disease, line of therapy, biomarker distribution, dose, follow-up, endpoint definitions and whether the study was randomised.

Toxicity is product-specific, not a single class list

ADCs as a group can cause infusion reactions, nausea, fatigue, cytopenias, infection, liver-test abnormalities, gastrointestinal symptoms and embryo-fetal harm. Which risks dominate, though, varies sharply from product to product. Current US labels show the spread:

trastuzumab deruxtecan carries a boxed warning for interstitial lung disease (ILD)/pneumonitis and requires prompt investigation of new cough, shortness of breath, fever or other respiratory change [6];
mirvetuximab soravtansine has boxed ocular warnings and scheduled visual-acuity and slit-lamp examinations [7];
enfortumab vedotin warns about serious skin reactions, hyperglycaemia, ILD/pneumonitis, peripheral neuropathy and ocular disorders [8];
sacituzumab govitecan has boxed warnings for severe neutropenia and diarrhoea, and reduced UGT1A1 activity can increase haematological risk [9].

None of these US examples replaces the current Chinese label or trial protocol. What they show is why no centre should hand every ADC patient the same generic warning sheet.

Before the first infusion, the team should set a baseline matched to the product: complete blood count, liver and renal function, pregnancy status where applicable, medicines and interactions, performance status and an infection review. Depending on the ADC, that baseline may also cover chest symptoms or imaging, an eye examination, neurological findings, glucose, cardiac function or electrolytes.

Between cycles, report symptoms early instead of waiting for the next scheduled scan. New breathlessness, a persistent cough, fever, visual change, eye pain, extensive rash or blistering, weakness or numbness, diarrhoea you cannot control, dehydration, bleeding or signs of infection can all need urgent assessment. Holding, reducing or stopping treatment is decided by the protocol or the label — never by a travel coordinator.

“Targeted delivery” does not eliminate systemic exposure

Linker instability, deconjugation, payload diffusion, target expression in normal tissue and ordinary drug clearance can all expose non-tumour tissues. A systematic review across approved ADC studies found associations between linker cleavability, drug-to-antibody ratio, free payload and systemic toxicity, and it also showed that these design variables interact [10]. So you cannot rank ADCs by linker type alone; the complete molecule and its clinical data are what matter.

Why resistance can occur despite target expression

An ADC can fail from the start, or work for a while and then stop. Tumours can reduce or vary antigen expression, internalise the complex poorly, reroute intracellular trafficking, alter lysosomal processing, pump the payload out or become resistant to the payload’s cellular target. Peer-reviewed literature summarises these ADC-specific resistance pathways [11].

A repeat biopsy or a new biomarker test can sometimes answer a real question, but it is not automatically needed, and it will not settle everything on its own. Ask the oncologist two things: what decision would the new tissue change, and is the procedure risk justified?

Sequencing and combinations deserve their own discussion

Two ADCs aimed at the same antigen can carry different payloads; two ADCs with similar payloads can aim at different antigens. Prior exposure can matter even when the next antibody is different, through residual organ toxicity or payload resistance. Whether one ADC should follow another is a disease- and product-specific question.

Combinations add another layer. An immune checkpoint inhibitor can bring immune-mediated pneumonitis, and the ADC itself may carry an ILD signal. Chemotherapy can pile onto cytopenia or diarrhoea. Ask how the team plans to attribute and manage overlapping toxicities — do not assume they can always tell right away which drug is responsible.

Plan repeated treatment, not just the first visit

Most ADC regimens mean recurring intravenous infusions and laboratory checks. A cross-border plan should spell out:

cycle dates and permitted delays;
which tests can be completed in the home country and how results reach the Chinese team;
infusion duration, observation and premedication;
local emergency access between cycles;
medicine supply for nausea, diarrhoea or other expected effects;
criteria for flying, especially when respiratory, ocular, neurological or blood-count toxicity is possible;
who decides dose holds and who records cumulative dose;
costs for biomarker testing, central review, study-only procedures, routine care and complications;
the treatment summary required if care transfers to another hospital.

After every cycle, an international patient should leave with the exact drug name, dose and date, the lot or administration record if available, any adverse events, dose changes, current medicines, the next required tests and a 24-hour clinical contact.

Seven questions to take to the oncologist

Is this exact ADC approved for my current disease and treatment line in China, or is it off-label or investigational?
Which specimen and assay establish my target result, and does the protocol require central confirmation?
What do the antibody, linker and payload each contribute to expected activity and risk?
Which toxicities are most important for this product, dose and combination?
What baseline and cycle-by-cycle monitoring will detect them early?
What evidence supports using this ADC after my prior therapies, especially another ADC or a similar payload?
If treatment is held or stopped abroad, who will manage the cancer and the toxicity at home?

Medical disclaimer: This guide is educational only. It does not recommend any ADC, decide eligibility or set doses. Treatment decisions belong to the treating oncology team, working from the current Chinese label or approved protocol, pathology, prior therapy, organ function and the available alternatives.

FAQ

Is an ADC simply a monoclonal antibody plus ordinary chemotherapy?

No. It is a chemically defined antibody-linker-payload product with a pharmacology of its own. The payload can be extremely potent, and release, distribution and toxicity all depend on the full construct.

Can I use an older pathology result for trial screening?

Possibly. The protocol may require a particular assay, enough remaining tissue, central review or a recent biopsy. Have the site confirm what it accepts before you spend money on tissue or travel.

If an ADC is approved overseas, can a Chinese hospital provide it as approved care?

Not on that fact alone. Check the current NMPA approval, the Chinese indication, the exact product and the regimen. If they do not line up, ask the hospital to state clearly whether the proposal is off-label care or a registered clinical trial.